The Wall Street Journal @WSJ

From @WSJopinion: Eli Lilly and Novo Nordisk are trying to transform how patients access medication, and Washington has done its part. It’s time to let consumers roar into a competitive marketplace—without government intervention, writes Stephen Buck. https://t.co/OKYWoEYHl1

www.wsj.com

Opinion | Your Wegovy May Pay for Itself

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.